Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIF001 Monoclonal Antibody in Treatment-Resistant Depression
ChiCTR2500110093Phase 2Not yet recruiting
- Sponsor
- The First Hospital of Hebei Medical University
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SIF001 in treatment-resistant depression (TRD), sponsored by The First Hospital of Hebei Medical University. Primary endpoints: Hamilton Depression Rating Scale (HAMD) score and Safety parameters (laboratory tests and vital signs). Planned start Sep 2025; status: not yet recruiting.
02
Drugs
SIF001
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on ChiCTR2500110093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110093.